Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature

Theo F. J. Kraus1 · Lukas Machegger2 · Johannes Pöppe3 · Barbara Zellinger1 · Eva Dovjak1 · Hans U. Schlicker1 · Christoph Schwartz2 · Barbara Ladisich3 · Mathias Spendel3 · Michael Kral3 · Annekathrin Reinhardt4 · Peter A. Winkler3 · Karl Sotlar1

Received: 28 April 2020 / Accepted: 8 May 2020 / Published online: 25 May 2020 © The Author(s) 2020

Abstract

Here, we report on a 28-year old male patient presenting with neck and shoulder pain, dysesthesia of all four limbs, and hypesthesia of both hands, without motor deficits. Magnetic resonance imaging showed an intradural, intramedullary mass of the cervical spinal cord of 6.4 cm length and 1.7 cm diameter. The patient underwent surgical resection. Histological and immunohistochemical evaluation showed pleomorphic glial tumor cells, mitoses, calcifications, and atypical ganglioid cells compatible with the morphology of anaplastic ganglioglioma (WHO Grade III). Extensive molecular workup revealed H3F3A K27M, TERT C228T and PDGFRα Y849C mutations indicating poor prognosis. The H3F3A K27M mutation assigned the tumor to the molecular group of diffuse midline glioma (WHO Grade IV). Epigenome-wide methylation profiling confirmed the methylation class of diffuse midline glioma. Thus, this is a very rare case of malignant glioma with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma. This case emphasizes the importance of comprehensive morphological and molecular workup including methylome profiling for advanced patient care.

Keywords Anaplastic ganglioglioma · Diffuse midline glioma · H3F3A K27M · TERT C228T · PDGFRα Y849C · Methylome analysis

Introduction

In the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS) molecular genomic and epigenomic hallmarks were integrated into the classification and diagnosis of several brain tumors [1]. This development was the consequence of previous studies that revealed distinct methylation profiles defining novel entities [2–7]. One of the most prominent examples is the entity “diffuse midline glioma H3 K27M mutant” [1], typically arising within midline structures and the brain stem in younger patients [2]. Since these tumors show a devastating prognosis, they are assigned to WHO grade IV [1]. The characteristic hallmark of diffuse midline gliomas is the unique genotype of the tumors carrying the K27M mutation within one of the histone genes H3F3A, HIST1H3B or HIST1H3C.[2, 8, 9] In contrast to the nearly invariant mutations, these tumors show a highly variable histological phenotype mimicking numerous other tumors of the CNS such as glioblastoma, primitive neuroectodermal tumors, medulloblastomas but also low-grade gliomas [2, 9].

Gangliogliomas are rare glioneuronal tumors accounting for approximately 1.3% of all primary brain tumors [1]. They are frequently associated with epilepsy and are commonly located within the temporal lobe in younger patients [1].
Molecular genetic testing revealed that the **BRAF V600E** mutation is frequently found in gangliogliomas [1]. Since these tumors show a relatively benign behavior and malignant progression is rare, they are assigned to WHO grade I [1]. However, in 3–5% of all gangliogliomas anaplastic variants can be found: [1, 10–15]. In these cases, the glial component shows signs of anaplasia, increased proliferation activity and an increased mitotic count [1, 15]. These rare tumors are currently classified as anaplastic gangliogliomas and are assigned to WHO grade III. They show an unfavorable outcome [1, 15].

Here, we report of a malignant tumor of the cervical spinal cord in a 28-year old male patient with morphology of anaplastic ganglioglioma but genotype of diffuse midline glioma H3 K27M mutant.

**Clinical summary**

A 28-year old male Caucasian presented with neck and shoulder pain, dysesthesia of all four limbs and hypesthesia affecting both hands, without motor deficits. Magnetic resonance imaging (MRI) showed an intradural, intramedullary mass of the cervical spinal cord at levels C2–C6 of 6.4 cm length and 1.7 cm diameter with distinct expansion of the myelon. T2 weighted sequences showed an inhomogeneous, hyperintense lesion with a consecutive syringomyelia ranging from C6/7 to T1/2 with a length of 4 cm and a maximum diameter of 0.7 cm (Fig. 1a, b). In T1 weighted imaging the lesion was iso- to hypointense with a mild to moderate, inhomogeneous contrast enhancement in the central parts without evidence of hemorrhage (hemosiderin capping), therefore primarily suspicious for glioma or ependymoma (Fig. 1c, d). Preoperative median nerve somatosensory evoked potentials (SSEP) were normal, with a deceleration of tibial nerve SSEPs on both sides indicating an impairment of spino-thalamo-cortical fibers.

The patient underwent surgical resection of the tumor through laminoplasty C2–C6 using intraoperative neurophysiological monitoring with SSEPs. Intraoperative findings showed a solid, grey and partially bleeding tumor mass with infiltration of the surrounding myelon. Therefore, after intraoperative deterioration of evoked potentials a complete resection could not be achieved. Postoperative MRI scans showed a partial resection with minimal residual contrast enhancement in T1 images and residual T2-hyperintense tumor lesions. In postoperative clinical examination the patient showed an incomplete cross-sectional sensorimotor syndrome from C4 that gradually declined under physical therapy. Concomitant radiochemotherapy with

---

**Fig. 1** Radiological findings. Sagittal (a) and axial (b) T2 weighted magnetic resonance imaging (MRI) showing an inhomogeneous hyperintense intramedullary tumor in the upper cervical cord with a consecutive syringomyelia below the lesion. Sagittal (c) and axial (d) postcontrast T1 weighted imaging demonstrating a mild and inhomogeneous contrast enhancement in the central parts of the lesion with minimal central hemorrhage (without hemosiderin capping)
Temozolomide analogous to STUPP protocol [16] was initiated after diagnosis with a local application of $28 \times 1.8$ Gy including residual tumor volume and high risk areas.

**Pathological findings**

Histologically, the H&E staining showed a pleomorphic glial tumor with calcifications (Fig. 2a-c). Partially, the tumor cells were very round with only short processes and perinuclear halos (Fig. 2b), and mitotic activity was increased. Frequently, there were neuronal cells with multiple nuclei intermingled within glial tumor cells (Fig. 2c).

Immunohistochemistry performed on a Ventana Bench-mark Ultra System with standard protocols showed that glial tumor cells were positive for GFAP (glial fibrillary acidic protein, Fig. 2d). Nuclear expression of ATRX (nuclear immunopositivity for $\alpha$-thalassemia/mental-retardation-syndrome-X-linked) was retained (Fig. 2e) and there was no expression of IDH1 (isocitrate dehydrogenase 1) R132H mutant protein (Fig. 2f). Tumor cells were negative for EMA (Fig. 2g). Neuronal cells were positive for synaptophysin (Fig. 2h) and some tumor cells showing positivity for CD34 (Fig. 2i). Immunohistochemistry with an antibody against mutant histone H3.3 K27M (Fig. 2j) showed nuclear staining in most of the tumor cells. Proliferation was increased with

**Fig. 2** Histological and immunohistochemical findings. In H&E stained sections, mildly to highly pleomorphic glial tumor cells with glial cell processes and hemorrhages were detected (a). Calcifications and very round tumor cells with only short processes and perinuclear halos (b), intermingled within neuronal cells showing dysmorphic appearance, were also visible (c). Immunohistochemistry showed tumor cells being positive for GFAP (d) with retained ATRX expression (e), and no expression of IDH1 R132H mutant protein (f). Tumor cells were negative for EMA (g). Ganglionic cells were positive for synaptophysin (h) and there were some CD34 positive tumor cells (i). Histone H3.3 K27M mutant protein was strongly expressed in the nuclei of tumor cells (j). Ki67 index showed 20% positive cells (k) and there were some PHH3 (H3S10p) positive cells (l). Magnification: a: 10×, b: 20×, c–l: 40×
20% Ki67 positive cells (Fig. 2k) and some PHH3 (phosphorylated histone H3, H3S10p) positive cells (Fig. 2l).

Molecular genetic analysis of the 1p and 19q status was performed by fluorescence in situ hybridization (FISH) using standard protocols. Analysis showed 16 out of 100 cells with a loss of chromosomal information on 1p compared with 1q (Fig. 3a) and eight out of 100 cells with a loss of chromosomal information on 19q compared to 19p (Fig. 3b). Thus, there was no evidence for a combined 1p/19q loss within the tumor.

Analysis of gene mutations was performed by DNA extraction using the Maxwell system (Promega) according to the manufacturer’s protocol and subsequent application of the AmpliSeq for Illumina Cancer Hotspot Panel v2 (Illumina) on an Illumina MiniSeq next generation sequencing device (Illumina) according to the manufacturer’s protocols. Additionally, Sanger sequencing on hot spot loci of TERT promoter, H3F3A, HIST1H3B and HIST1H3C genes was performed.

Mutational analysis confirmed the H3F3A (K27M) mutation (Fig. 3c) and revealed a TERT (C228T) promoter (Fig. 3d) and PDGFRα (Y849C) gene mutation (Fig. 3e). There was no mutation at the hot-spot regions of all other 51 genes investigated including BRAF, HISH1H3B, HIST1H3C, IDH1, and IDH2 (Fig. 3f).

Additionally, epigenome-wide methylation profiling was performed at the Department of Neuropathology, University Hospital Heidelberg/German Cancer Research Center (DKFZ), using Illumina EPIC methylation bead chips [9]. This procedure enables to assign brain tumors according to their methylome to distinct molecular entities [9]. Well in line with the detection of the H3F3A K27M mutation, the tumor was allocated to the methylation class of diffuse midline glioma H3 K27M mutant (brain tumor classifier V11b4, Fig. 3g).

**Discussion**

Diffuse midline gliomas H3 K27M mutant are rare tumors that typically arise within midline structures and the brain stem in younger patients [1, 2, 8]. These tumors show a devastating prognosis [1]. Diffuse midline gliomas have been shown by performing epigenome-wide methylation profiling to constitute a distinct methylation class [2]. Interestingly, diffuse midline gliomas show a broad range of phenotypes mimicking glioblastomas, primitive neuroectodermal tumors, medulloblastomas or even low-grade gliomas and glio-neuronal tumors [2, 9]. In contrast to the highly variable histological phenotype diffuse midline gliomas show a distinct genotype carrying the K27M mutation within the histone genes H3F3A, HIST1H3B or HIST1H3C [2, 8, 9].

In the case presented here, a tumor of the cervical spinal cord with histological appearance of ganglioglioma was found. Since mitotic activity was significantly increased, the tumor fulfilled the histological criteria for anaplastic ganglioglioma WHO Grade III (Fig. 2). Well in line with histology,
the tumor showed expression of both glial (e.g. GFAP) and neuronal markers (e.g. synaptophysin) with pathological expression of CD34 and retained ATRX expression (Fig. 2). Proliferative activity assessed by Ki67 immunohistochemistry was significantly increased up to 20% (Fig. 2). Molecular workup showed no IDH1, IDH2, and BRAF mutations but revealed H3F3A K27M, TERT promoter (C228T) and PDGFRA Y849C mutations (Fig. 3).

Thus, the tumor showed the molecular hallmark of diffuse midline glioma H3 K27M mutant [1]. Well in line with this diagnosis was the epigenome-wide methylation analysis, allotting the tumor to the methylation class of diffuse midline glioma. Interestingly, additional PDGFRA Y849C and TERT promoter (C228T) mutations have been detected. While neither of these mutations have been described frequently in anaplastic ganglioglioma or diffuse midline glioma H3 K27M mutant, they both may point towards higher malignancy: The Y849 position of PDGFRA is of functional importance [17] and aberrant expression of PDGFRA [18] and TERT promoter mutations typically are frequently observed in glioblastoma, however, TERT promoter mutations also occur very frequently in oligodendroglioma WHO grade II [19, 20].

To our knowledge, this is the first reported case of a diffuse midline glioma H3 K27M mutated phenotypically mimicking anaplastic ganglioglioma that was confirmed by methylene profiling and carrying further TERT, and PDGFRA mutations.

A literature search revealed ten cases of phenotypical gangliogliomas WHO Grade I and three cases of anaplastic gangliogliomas WHO Grade III carrying the H3 K27M genotype [21–25]. Interestingly, seven of these ten gangliogliomas showed carried a BRAF V600E mutation [22]. All previously reported phenotypical anaplastic gangliogliomas WHO Grade III with H3 K27M genotype lacked BRAF V600E mutation [22]. This may indicate that some diffuse midline gliomas H3 K27M mutant are misinterpreted as anaplastic ganglioglioma. However, no methylene analyses has been performed in those cases. In a few cases double mutations of H3F3A K27M and BRAF V600E have been described [26, 27]. No systematic epigenome-wide methylation profiling of such tumors has been performed to date.

Longer survival in tumors with both BRAF V600E and H3 K27M mutations however suggest that these tumors should be separated from canonical diffuse glioma H3 K27M mutant [27]. Our case emphasis the importance of an integrated molecular workup including methylene profiling in rare and not clearly defined tumor entities.

In summary, the case presented here is a very rare example of diffuse midline glioma H3 K27M mutant phenotypically mimicking anaplastic ganglioglioma. It seems that the phenotypes of ganglioglioma and anaplastic ganglioglioma in parts represent heterogeneous groups of tumors in terms of their molecular background. Thus, there is the urgent need for combining both histology and molecular pathology including methylene analysis for advanced integrated diagnosis in glial and glioneuronal tumors. In an analogous manner to the introduction of integrated diagnosis in glioma with the 2016 WHO classification of tumors of the CNS [1] this will enable a refined patient care by introducing new individualized treatment strategies including targeted antibody therapies.

Acknowledgement Open access funding provided by Paracelsus Medical University. We would like to thank Prof. von Deimling, Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, DKFZ, for performing epigenomic tumor profiling. We also thank the members of the histology, immunohistochemistry and molecular pathology facilities at the Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, for their support in conducting this study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Ethical approval All procedures performed in studies were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Louis DN et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

2. Sturm D et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. https://doi.org/10.1016/j.ccr.2012.08.024

3. Halliday GC et al (2018) The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. J Clin Neurosci 47:163–167. https://doi.org/10.1016/j.jocn.2017.09.013

4. Sahm F et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective
analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9
5. Pajtler KW et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743. https://doi.org/10.1016/j.ccell.2015.04.002
6. Capper D et al (2018) Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol 136:181–210. https://doi.org/10.1007/s00401-018-1879-y
7. Jaunmuktane Z et al (2019) Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol Commun 7:24. https://doi.org/10.1186/s40478-019-0668-8
8. Schwartzentruber J et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231. https://doi.org/10.1038/nature10833
9. Capper D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000
10. Luyken C et al (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101:146–155. https://doi.org/10.1002/cncr.20332
11. Lang FF et al (1993) Central nervous system gangliogliomas. Part 2: clinical outcome. J Neurosurg 79:867–873. https://doi.org/10.3171/jns.1993.79.6.0867
12. Miller DC, Lang FF, Epstein FJ (1993) Central nervous system gangliogliomas. Part 1: pathology. J Neurosurg 79:859–866. https://doi.org/10.3171/jns.1993.79.6.0859
13. Wolf HK et al (1994) Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol 88:166–173. https://doi.org/10.1007/bf00294510
14. Zentner J et al (1994) Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57:1497–1502. https://doi.org/10.1136/jnnp.57.12.1497
15. Lucas JT Jr et al (2015) Anaplastic ganglioglioma: a report of three cases and review of the literature. J Neurooncol 123:171–177. https://doi.org/10.1007/s10937-015-1781-6
16. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
17. Heldin CH, Lennartsson J (2013) Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol 5:a009100. https://doi.org/10.1101/cshperspect.a009100
18. Cantanhede IG, de Oliveira JRM (2017) PDGF family expression in glioblastoma multiforme: data compilation from ivy glioblastoma atlas project database. Sci Rep 7:15271. https://doi.org/10.1038/s41598-017-15045-w
19. Eckel-Passow JE et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279
20. Liu J et al (2019) Significance of TERT and ATRX mutations in glioma. Oncol Lett 17:95–102. https://doi.org/10.3892/ol.2018.9634
21. Kleinschmidt-DeMasters BK, Donson A, Foreman NK, Dorris K (2017) H3 K27M mutation in gangliogliomas can be associated with poor prognosis. Brain Pathol 27:846–850. https://doi.org/10.1111/bpa.12455
22. Okuda T et al (2018) Pediatric ganglioglioma with an H3 K27M mutation arising from the cervical spinal cord. Neuropathology. https://doi.org/10.1111/neup.12471
23. Zanello M et al (2016) Clinical, imaging, histopathological and molecular characterization of anaplastic ganglioglioma. J Neuropathol Exp Neurol 75:971–980. https://doi.org/10.1093/jnen/nlw074
24. Joyon N et al (2017) K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol 43:271–276. https://doi.org/10.1111/nan.12329
25. Pages M et al (2018) Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol 28:103–111. https://doi.org/10.1111/bpa.12473
26. Nguyen AT et al (2015) Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol 41:403–408. https://doi.org/10.1111/nan.12196
27. Nakano Y et al (2019) A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations. Brain Tumor Pathol 36:162–168. https://doi.org/10.1007/s10014-019-00347-w

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.